126 / 1084
Oesophageal Cancer – CROSS Study (I+II)
CROSS I and II study
(n=418)
Relapse
After Resection
(n=161)
n %
After RCTx+
Resection (n=213)
n %
HR P-
value
© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick
Oppedijk et al.
J Clin Oncol
2014; 32:385-391
Distant disease control is still not
optimal with the CROSS regimen
Mediastinum
33
20.5%
15
7.0%
0.29 <0.001
Hematogenous
57
35.4%
61
28.5%
0.67 0.03